BR0314943A - Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes - Google Patents

Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes

Info

Publication number
BR0314943A
BR0314943A BR0314943-9A BR0314943A BR0314943A BR 0314943 A BR0314943 A BR 0314943A BR 0314943 A BR0314943 A BR 0314943A BR 0314943 A BR0314943 A BR 0314943A
Authority
BR
Brazil
Prior art keywords
cftr
cystic fibrosis
thiazolidinone
methods
transmembrane conductance
Prior art date
Application number
BR0314943-9A
Other languages
English (en)
Inventor
Alan Verkman
Tonghui Ma
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en
Application filed by Univ California filed Critical Univ California
Publication of BR0314943A publication Critical patent/BR0314943A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Abstract

"INIBIDORES DA PROTEìNA REGULADORA DA CONDUTâNCIA TRANSMEMBRANA DA FIBROSE CìSTICA E USOS DESTES". A invenção fornece composições, preparações farmacêuticas e métodos para inibição da proteína reguladora da condutância transmembrana da fibrose cística (CFTR) que são usados para o estudo e tratamento de doenças e condições mediadas por CFTR. As composições e preparações farmacêuticas da invenção podem compreender um ou mais compostos tiazolidinona e podem adicionalmente compreender um ou mais veículos, excipientes e/ou adjuvantes farmaceuticamente aceitáveis. Os métodos da invenção compreendem, em certas modalidades, administrar a um paciente que sofre de uma doença ou condição mediadas por CFTR, uma quantidade eficaz de um composto tiazolidinona. Em outras modalidades a invenção fornece métodos de inibir CFTR que compreendem colocar as células de um sujeito em contato com uma quantidade efetiva de um composto tiazolidinona. Além do mais, a invenção caracteriza um modelo animal não humano de doença mediada pelo CFTR, modelo este que é produzido pela administração de um composto tiazolidinona a um animal não humano em uma quantidade suficiente para inibir o CFTR.
BR0314943-9A 2002-09-30 2003-09-30 Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes BR0314943A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/262,573 US20040063695A1 (en) 2002-09-30 2002-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US48025303P 2003-06-20 2003-06-20
PCT/US2003/031005 WO2004028480A2 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR0314943A true BR0314943A (pt) 2005-08-02

Family

ID=32044981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314943-9A BR0314943A (pt) 2002-09-30 2003-09-30 Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes

Country Status (13)

Country Link
EP (1) EP1549321A4 (pt)
JP (1) JP4977319B2 (pt)
KR (1) KR20050061501A (pt)
CN (1) CN100356922C (pt)
AP (1) AP2005003292A0 (pt)
AU (1) AU2003277162C1 (pt)
BR (1) BR0314943A (pt)
CA (1) CA2500498C (pt)
EA (1) EA009847B1 (pt)
MX (1) MXPA05003366A (pt)
NZ (1) NZ538809A (pt)
PL (1) PL376147A1 (pt)
WO (1) WO2004028480A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CN101460489A (zh) 2006-04-07 2009-06-17 弗特克斯药品有限公司 Atp-结合盒转运蛋白调节剂
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
NZ583420A (en) * 2007-08-24 2012-06-29 Vertex Pharma Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
NZ585980A (en) 2007-11-16 2012-04-27 Vertex Pharma Isoquinoline modulators of atp-binding cassette transporters
SG186638A1 (en) 2007-12-07 2013-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
KR20100134063A (ko) * 2008-03-25 2010-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 낭포성 섬유증 막투과 전도성 조절자의 수용성 소분자 억제제
PT2615085E (pt) 2008-03-31 2015-10-09 Vertex Pharma Derivados piridilo como moduladores cftr
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2490696A1 (en) * 2009-10-20 2012-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
DK2826776T3 (da) 2010-03-25 2020-12-14 Vertex Pharma Fast dispersion af amorf form af (r)-1(2,2-difluorbenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
PL2555754T3 (pl) 2010-04-07 2016-09-30 Formy stałe kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
RU2013112937A (ru) 2010-08-23 2014-09-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение
CN102133402B (zh) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用
US9056862B2 (en) 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2015504920A (ja) 2012-01-25 2015-02-16 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の製剤
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
SG10201703452PA (en) 2012-11-02 2017-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
FR2999191B1 (fr) 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
EP4223294A1 (en) 2014-04-15 2023-08-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
LT3203840T (lt) 2014-10-06 2020-10-26 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai
CN104398509B (zh) * 2014-11-13 2017-01-11 四川大学华西第二医院 CFTR抑制剂CFTRinh-172在制备防治白血病细胞介导的疾病的药物中的应用
CN104788423B (zh) * 2015-03-13 2016-10-26 成都理工大学 一种新的囊性纤维化跨膜传导调节因子抑制剂
BR112018012927A2 (pt) 2015-12-24 2018-12-11 Univ California reguladores cftr e métodos de uso dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9010041B (en) * 1989-12-21 1992-08-26 Lilly Co Eli Compounds for treating inflammatory bowel disease
EP0728003A1 (en) * 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
JP2002523371A (ja) * 1998-08-21 2002-07-30 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法
US6484397B1 (en) * 2000-07-11 2002-11-26 Corning Incorporated Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Also Published As

Publication number Publication date
AU2003277162A1 (en) 2004-04-19
EP1549321A4 (en) 2007-05-23
EA200500583A1 (ru) 2005-12-29
JP4977319B2 (ja) 2012-07-18
PL376147A1 (en) 2005-12-27
AP2005003292A0 (en) 2005-06-30
KR20050061501A (ko) 2005-06-22
WO2004028480A3 (en) 2004-07-01
CA2500498C (en) 2012-08-21
WO2004028480A2 (en) 2004-04-08
NZ538809A (en) 2008-06-30
CA2500498A1 (en) 2004-04-08
MXPA05003366A (es) 2005-10-05
CN100356922C (zh) 2007-12-26
JP2006503853A (ja) 2006-02-02
EP1549321A2 (en) 2005-07-06
AU2003277162B2 (en) 2009-07-16
AU2003277162C1 (en) 2009-12-24
CN1684686A (zh) 2005-10-19
EA009847B1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BRPI0509282A (pt) compostos contendo hidrazida inibidores de cftr e seus usos
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
ECSP056182A (es) Derivados de carbostirilo y estabilizantes del estado de ánimo para tratar trastornos del mismo
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR0110420A (pt) Agonistas muscarìnicos
EP1369119B1 (en) Il-12 expression controlling agents
AR033688A1 (es) Composicion parenteral reconstituible
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
EA200501105A1 (ru) Фармацевтическая композиция
KR970025615A (ko) 암 전이 억제제
DE69733089D1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
BR9909872A (pt) uso de dexmedetomidina para uma unidade de sedação de proteção intensiva
Sukhov et al. Long-term intranasal insulin administration improves spatial memory in male rats with prolonged type 1 diabetes mellitus and in healthy rats
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
Bikman et al. Metformin Improves Insulin Signaling in Obese Rats via Reduced IKK Action in a Fiber-Type Specific Manner
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
RU2679447C1 (ru) Применение L-лизина тиазотата как активной основы лекарственных средств гепатопротекторного и детоксикационного действия

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI.A61K 31/549, A61P 11/00, A61P 1/12

Ipc: A61K 31/549 (2011.01), A61P 11/00 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2273 DE 29/07/2014.